Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.
Journal: The lancet. Diabetes & endocrinology
Published: July 02, 2025
Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary.
Journal: Future cardiology
Published: June 23, 2025
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.
Journal: The lancet. Diabetes & endocrinology
Published: July 22, 2024
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy.
Journal: European heart journal
Published: October 20, 2023
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition.
Journal: European heart journal. Cardiovascular pharmacotherapy
Published: July 11, 2022
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.
Journal: JAMA
Published: April 03, 2022
Targeting PCSK9 inhibitors to those who will benefit most.
Journal: The lancet. Diabetes & endocrinology
Published: February 21, 2022
Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: September 04, 2020
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Journal: The New England journal of medicine
Published: March 21, 2020
Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder.
Journal: The mental health clinician
Published: June 30, 2018
Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)".
Journal: Circulation
Published: February 13, 2018
Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
Journal: Expert review of cardiovascular therapy
Published: June 28, 2017
Last Updated: 09/26/2026